Lonsurf (trifluridine/tipiracil)

pCPA File Number: 22614
Negotiation Status:
Under consideration for negotiation
Indication(s):
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Sponsor/Manufacturer:
Taiho Pharma Canada Inc.
CADTH Project Number:
PC0330-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable